Brief: Argent BioPharma Posts HY Net Loss Attributable A$12.2 Million
28/02/2025 08:19
Feb 28 (Reuters) - Argent BioPharma Ltd RGT.AX: HY NET LOSS ATTRIBUTABLE A$12.2 MILLION Source text: ID:nASX2LZQkC Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program